Feliciano EMC, et al. – This study strived to assess muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant leucovorin calcium/calcium folinate, 5-fluorouracil, and oxaliplatin (FOLFOX). Among patients receiving FOLFOX, an association was observed between lower muscle mass and greater toxicity as well as poor chemotherapy adherence. Although treatment seemed to be better individualized if muscle mass was considered, many chemotherapy drugs were dosed based on body surface area (BSA).